Home » Newsletters » BioWorld Science

BioWorld Science

March 28, 2000

View Archived Issues

German collaboration in colorectal cancer research announced

Promising phase I/II results reported by Collateral for Generx

Glaxo Wellcome expands DNA vaccine program with PowderJect

ICAgen and Children's Hospital of Boston to develop novel therapeutics

Celltech and Cistron enter merger agreement

Novel drug target for treatment of antibiotic-resistant bacteria discovered by Antex

Clinical trial results show DigiTAb to be safe and effective for oleander poisoning

American Biogenetic Sciences to humanize its MH-1 antibody

Immune Network Research branches out into hepatitis C

Janssen to cease cisapride marketing in the U.S.

Nonpeptide protease inhibitors designed and evaluated at 3-D

Novel therapies for atherosclerosis in early development at Bayer

Neurogen patents new series of compounds that selectively bind to brain GABA-A receptors

Ligand presents new nonsecosteroidal vitamin D mimics, their activity and use

Pfizer's new macrolides disclosed in recent patent

Development and use of gene-based multivalent malaria vaccine

SRL-172 associated with significantly improved survival in SCLC patients

FDA advisory committee gives thumbs-up to Zyvox

ACS news: Texas Biotechnology presents synthesis, activity of new VLA-4 antagonist

Novel drug-coated stent associated with significantly less restenosis

Recent R&D in PTP1B inhibitors discussed by Pharmacia & Upjohn at ACS meeting

DaTSCAN receives positive opinion from the CPMP

Ontogen describes results of high-throughput screening for PTP1B inhibitors

Newly designed enzyme inhibitors may lead to novel therapeutics for Alzheimer's

Two novel muscle relaxants designed by Eisai characterized at ACS national meeting

New developments in the area of diabetes therapeutics at Sanwa Kagaku

Tacrolimus for stroke; efficacy, mechanisms, etc. discussed at Japanese meeting

Cell Therapeutics to submit NDA for arsenic trioxide by the end of March